eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
abstract:
Original paper

Changes in liver stiffness and steatosis in children after successful treatment with sofosbuvir/velpatasvir: Results of the PANDAA-PED study

Maria Pokorska-Śpiewak
1, 2
,
Ewa Talarek
1, 2
,
Małgorzata Aniszewska
1, 2
,
Magdalena Pluta
1, 2
,
Anna Dobrzeniecka
1, 2
,
Magdalena Marczyńska
1, 2
,
Giuseppe Indolfi
3, 4

  1. Department of Children’s Infectious Diseases, Medical University of Warsaw, Poland
  2. Warsaw Hospital for Infectious Diseases, Warsaw, Poland
  3. Department of Neurofarba, Meyer Children’s University of Florence, Italy
  4. Meyer Children’s Hospital IRCCS, Florence, Italy
Clin Exp HEPATOL 2025; 11, 1
DOI: https://doi.org/10.5114/ceh.2024.146131
Online publish date: 2024/12/19
View full text Get citation
 
PlumX metrics:
Aim of the study:
The aim of this study was to analyze changes in liver stiffness and steatosis using noninvasive methods in children aged 6 to 18 years up to one year after successful treatment with sofosbuvir/velpatasvir (SOF/VEL).

Material and methods
Evaluation of liver stiffness and steatosis was performed in 49 patients at 12 weeks and one year after treatment using noninvasive methods. Liver stiffness measurement (LSM) and the controlled attenuation parameter (CAP) were obtained by transient elastography (FibroScan 530, Echosens).

Results
At baseline, LSM corresponded to a METAVIR F score of 0/1 in 48/49 (98%) participants. There was a decrease in mean LSM values from baseline to posttreatment visits (from 4.63 kPa to 4.26 kPa at 12 weeks, and 4.15 kPa at one year after treatment). In one girl who presented with significant fibrosis (LSM 11.3 kPa, F3) before the treatment, regression of stiffness was observed to 7.6 kPa (F2) at 12 weeks after treatment and 5.4 kPa (F0/1) at one year after treatment. There was an increase in the mean CAP value of +12.44 dB/m at 12 weeks after treatment compared to baseline, but the difference at one year after treatment was insignificant. A correlation between higher CAP values and older participants’ age was observed at all the visits. Children with body mass index (BMI) z-score values > 1.0 presented with higher CAP values both before and after treatment.

Conclusions
Most children with chronic hepatitis C present with normal liver stiffness. However, its regression may occur to some extent after successful treatment with SOF/VEL. A transient increase in hepatic steatosis was observed after eradication of HCV, which requires further investigation.

keywords:

liver fibrosis, liver stiffness, steatosis, hepatitis C, sofosbuvir/velpatasvir
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.